A Phase 1, Open-Label, Single-Dose, Two-Period, Fixed Sequence, Crossover Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Divarasib in Healthy Subjects
Latest Information Update: 19 Dec 2024
Price :
$35 *
At a glance
- Drugs Divarasib (Primary) ; Itraconazole (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Genentech
- 13 Dec 2024 Planned End Date changed from 18 Jan 2025 to 25 Jul 2025.
- 13 Dec 2024 Planned primary completion date changed from 18 Jan 2025 to 25 Jul 2025.
- 13 Dec 2024 Status changed from not yet recruiting to recruiting.